| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/28/2007 | EP1755603A2 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity |
| 02/28/2007 | EP1755602A1 Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid (a beta 40 and a beta 42) generation |
| 02/28/2007 | EP1755601A2 Inhibitors of histone deacetylase |
| 02/28/2007 | EP1755600A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| 02/28/2007 | EP1755599A1 Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension |
| 02/28/2007 | EP1755598A1 Methods for treating arthritic conditions in dogs |
| 02/28/2007 | EP1755597A2 Azaindoles modulating c-kit activity and uses therefor |
| 02/28/2007 | EP1755596A2 Process for preparing atazanavir bisulfate and novel forms |
| 02/28/2007 | EP1755595A1 Use of roflumilast for the prophylaxis or treatment of emphysema |
| 02/28/2007 | EP1755594A1 Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor |
| 02/28/2007 | EP1755593A1 Naphthaline derivatives useful as histamine-3-receptor ligands |
| 02/28/2007 | EP1755592A1 Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy |
| 02/28/2007 | EP1755591A2 Ophthalmic formulations including selective alpha 1 antagonists |
| 02/28/2007 | EP1755590A1 Combinations of glycopyrrolate and beta2 adrenoceptor agonists |
| 02/28/2007 | EP1755589A1 Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
| 02/28/2007 | EP1755588A1 Compounds and compositions for treatment of cancer |
| 02/28/2007 | EP1755587A1 Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof |
| 02/28/2007 | EP1755586A2 Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| 02/28/2007 | EP1755585A1 Transthyretin stabilization |
| 02/28/2007 | EP1755584A1 Treatment of myopia |
| 02/28/2007 | EP1755583A1 Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective |
| 02/28/2007 | EP1755582A1 Pharmaceutical compositions for the prevention and treatment of atherosclerosis |
| 02/28/2007 | EP1755581A1 Methods and compositions for the treatment of myocardial conditions |
| 02/28/2007 | EP1755580A1 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids |
| 02/28/2007 | EP1755579A2 Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux |
| 02/28/2007 | EP1755578A2 Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance |
| 02/28/2007 | EP1755577A2 Novel use of peptide compounds for treating amyotrophic lateral sclerosis |
| 02/28/2007 | EP1755576A1 Antimicrobial compositions and methods for their use |
| 02/28/2007 | EP1755575A2 Antifungal drug delivery |
| 02/28/2007 | EP1755574A2 Pten inhibitors |
| 02/28/2007 | EP1755573A1 Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
| 02/28/2007 | EP1755572A2 N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators |
| 02/28/2007 | EP1755571A2 Methods for interfering with fibrosis |
| 02/28/2007 | EP1755568A1 Controlled release formulation for oral administration of metformin |
| 02/28/2007 | EP1755566A2 Stable pharmaceutical formulations of benzimidazole compounds |
| 02/28/2007 | EP1755565A2 Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid |
| 02/28/2007 | EP1755562A1 Folic acid-containing contraceptive |
| 02/28/2007 | EP1755561A2 Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines |
| 02/28/2007 | EP1755559A1 Bioavailable solid dosage forms of metaxalone |
| 02/28/2007 | EP1755555A2 Dry powder compositions of glycopyrrolate |
| 02/28/2007 | EP1755554A2 Heat sterilization of glucocorticosteroids |
| 02/28/2007 | EP1755542A1 Mequinol-based dermatological depigmenting composition |
| 02/28/2007 | EP1755541A2 Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent |
| 02/28/2007 | EP1755537A1 Methods and compositions for preventing or treating periodontal diseases |
| 02/28/2007 | EP1755409A1 Topical application of marine oils to foods |
| 02/28/2007 | EP1755406A1 Method and compositions for reducing oxidative stress in an animal |
| 02/28/2007 | EP1755401A1 Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport |
| 02/28/2007 | EP1755394A2 Cancer treatment method |
| 02/28/2007 | EP1755393A2 Methods of diminishing co-abuse potential |
| 02/28/2007 | EP1755391A2 Methods and compositions for treating neuropathies |
| 02/28/2007 | EP1755388A1 Mixed co-crystals and pharmaceutical compositions comprising the same |
| 02/28/2007 | EP1691892B1 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 02/28/2007 | EP1675621B1 Pharmaceutical compositions of lavendustin |
| 02/28/2007 | EP1656128A4 Treatment for acne vulgaris and method of use |
| 02/28/2007 | EP1651223B1 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts |
| 02/28/2007 | EP1626962B1 Benzamide inhibitors of the p2x7 receptor |
| 02/28/2007 | EP1622880B1 Substituted dihydrochinazolines having antiviral properties |
| 02/28/2007 | EP1615629A4 Peptide deformylase inhibitors |
| 02/28/2007 | EP1581538B1 Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| 02/28/2007 | EP1581227B1 A method for treating renal failure |
| 02/28/2007 | EP1572179B1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 02/28/2007 | EP1513532B1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 02/28/2007 | EP1509522B1 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands |
| 02/28/2007 | EP1507776B1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 02/28/2007 | EP1501795B1 Cinnamic acid amides |
| 02/28/2007 | EP1492771B1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents |
| 02/28/2007 | EP1482951B8 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| 02/28/2007 | EP1465893B1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo (3.2.1) octane, the preparation thereof and the application of same in therapeutics |
| 02/28/2007 | EP1461335B1 2-heteroarylcarboxylic acid amides |
| 02/28/2007 | EP1458703B1 Isochroman compounds for treatment of cns disorders |
| 02/28/2007 | EP1456209B1 A2a adenosine receptor antagonists |
| 02/28/2007 | EP1456197B1 Piperidine-2,6-diones that are heterocyclically substituted in position 3 |
| 02/28/2007 | EP1441734B1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| 02/28/2007 | EP1439832B1 Method of treating acne vulgaris using avermectin compound |
| 02/28/2007 | EP1429807B1 Combination of a nsaid and a pde-4 inhibitor |
| 02/28/2007 | EP1425286B1 Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
| 02/28/2007 | EP1418912B1 Isoxazolopyridinones |
| 02/28/2007 | EP1416812B1 Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level |
| 02/28/2007 | EP1415987B1 Nitrogenous aromatic ring compounds as anti cancer agents |
| 02/28/2007 | EP1397350B1 Isoquinolinone derivatives as parp inhibitors |
| 02/28/2007 | EP1392666B1 Biologically active methylene blue derivatives |
| 02/28/2007 | EP1392318B1 15-keto-prostaglandins for treating drug-induced constipation |
| 02/28/2007 | EP1387843B1 Method for obtaining pioglitazone as an antidiabetic agent |
| 02/28/2007 | EP1381397B1 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 02/28/2007 | EP1379505B1 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| 02/28/2007 | EP1379229B1 A jasmonate pharmaceutical composition for treatment of cancer |
| 02/28/2007 | EP1370531B1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| 02/28/2007 | EP1368094B1 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo- 1,5-a|-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 02/28/2007 | EP1343561B1 Serine protease inhibitors |
| 02/28/2007 | EP1337258A4 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 02/28/2007 | EP1309592B9 Substituted pyrazoles |
| 02/28/2007 | EP1296685B1 Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| 02/28/2007 | EP1272186B1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 02/28/2007 | EP1265606B9 Cell adhesion inhibitors |
| 02/28/2007 | EP1248848B1 Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides |
| 02/28/2007 | EP1240154B1 Serine protease inhibitors |
| 02/28/2007 | EP1239776B1 Surgical needle with weeping tip |
| 02/28/2007 | EP1189634B1 Treating prostate cancer with anti-erbb2 antibodies |
| 02/28/2007 | EP1178988B1 Compounds and therapeutic methods |
| 02/28/2007 | EP1178811B1 Electrolyte gels for maintaining hydration and rehydration |